journal article
LitStream Collection
Home
Elma Klein Kranenbarg, Cornells J. H. van de Velde
doi: 10.1093/jjco/29.4.185pmid: 10340040
Importance of Organizing Surgical Trials in Oncology deepdyve.host = 'www.deepdyve.com'; // replace with an affiliateId that we provide deepdyve.affiliateId = "highwire-oupjournals"; // the div to fill in with the rental link deepdyve.divIdList = ('rentalLink', 'rentalLink2'); // this is the anchor text for the rental link deepdyve.rentText = "Rent Article at DeepDyve"; deepdyve.divIdMap = {'rentalLink':'Rent Article at DeepDyve','rentalLink2':'Learn more here.'}; // document identifier and identifier type deepdyve.fieldName = 'journal_doi'; deepdyve.docId = "10.1093/jjco/29.4.185";
doi: 10.1093/jjco/29.4.187pmid: 10340041
Background: High levels of urokinase-type plasminogen activator (u-PA) weredemonstrated in gastric carcinomas along with inhibitors of plasminogen activators (PAI-1 and PAI-2). They may influence the ability to invade and metastasize and therefore be of importance to the risk of recurrence of stomach neoplasms after curative operation. This also appears to be the case for p53 mutations and p53 protein overexpression. Methods: Six patients, all differentiated cancer cases who developed recurrent disease 5–10 years after curative operations for early gastric cancers (recurrence group), were studied in comparison with 49 patients who had no recurrence more than 10 years after similar surgery (control group). The expression of u-PA, PAI-1, PAI-2 and p53 was compared immunohistochemically in the recurrence and control groups. Results: The expression of PAI-2 was significantly more frequent in the recurrence group, being found in five (83.3%) patients vs eight (16.3%) in the control group. p53 was expressed in five (83.3%) patients in the recurrence group and in 15 (30.6%) in the control group; the rate was again significantly higher in the former. Conclusion: The results suggest that PAI-2 and p53 expressed in differentiated early gastric cancers are possible indices of the risk of recurrence. Key words Key words early gastric cancer urokinase-type plasminogen activator plasminogen activator inhibitor types 1 and 2 p53 protein © 1999 Foundation for Promotion of Cancer Research « Previous | Next Article » Table of Contents This Article Jpn. J. Clin. Oncol. (1999) 29 (4): 187-191. doi: 10.1093/jjco/29.4.187 » Abstract Free Full Text (HTML) Free Full Text (PDF) Free Classifications Original Articles Services Article metrics Alert me when cited Alert me if corrected Find similar articles Similar articles in Web of Science Similar articles in PubMed Add to my archive Download citation Request Permissions Citing Articles Load citing article information Citing articles via CrossRef Citing articles via Scopus Citing articles via Web of Science Citing articles via Google Scholar Google Scholar Articles by Kammori, M. Articles by Hashimoto, H. Search for related content PubMed PubMed citation Articles by Kammori, M. Articles by Kaminishi, M. Articles by Kobayashi, K. Articles by Oohara, T. Articles by Endo, H. Articles by Takubo, K. Articles by Hashimoto, H. Related Content Load related web page information Share Email this article CiteULike Delicious Facebook Google+ Mendeley Twitter What's this? Search this journal: Advanced » Current Issue November 2015 45 (11) Alert me to new issues The Journal About this journal JJCO Editorial Office Rights & Permissions Dispatch date of the next issue This journal is a member of the Committee on Publication Ethics (COPE) We are mobile – find out more Journals Career Network Impact factor: 2.016 5-Yr impact factor: 2.036 Editor-in-Chief Tadao Kakizoe View full editorial board View/Download Reviewer Board List Thank you: Reviewers of 2014 For Authors Instructions to authors Online submission Online submission instruction Open Access options for authors - visit Oxford Open This journal enables compliance with the NIH Public Access Policy Self-archiving policy Alerting Services Email table of contents Email Advance Access CiteTrack XML RSS feed Corporate Services Advertising sales Reprints Supplements
Kammori, Makoto; Kaminishi, Michio; Kobayashi, Kaoru; Oohara, Takeshi; Endo, Hisako; Takubo, Kaiyo; Hashimoto, Hajime
doi: N/Apmid: N/A
Background: High levels of urokinase-type plasminogen activator (u-PA) weredemonstrated in gastric carcinomas along with inhibitors of plasminogen activators (PAI-1 and PAI-2). They may influence the ability to invade and metastasize and therefore be of importance to the risk of recurrence of stomach neoplasms after curative operation. This also appears to be the case for p53 mutations and p53 protein overexpression.Methods: Six patients, all differentiated cancer cases who developed recurrent disease 5–10 years after curative operations for early gastric cancers (recurrence group), were studied in comparison with 49 patients who had no recurrence more than 10 years after similar surgery (control group). The expression of u-PA, PAI-1, PAI-2 and p53 was compared immunohistochemically in the recurrence and control groups.Results: The expression of PAI-2 was significantly more frequent in the recurrence group, being found in five (83.3%) patients vs eight (16.3%) in the control group. p53 was expressed in five (83.3%) patients in the recurrence group and in 15 (30.6%) in the control group; the rate was again significantly higher in the former.Conclusion: The results suggest that PAI-2 and p53 expressed in differentiated early gastric cancers are possible indices of the risk of recurrence.
Makimoto, Takeyuki; Tsuchiya, Satoshi; Hayakawa, Kazushige; Saitoh, Ryusei; Mori, Masatomo
doi: N/Apmid: N/A
Background: Risk factors for severe radiation pneumonitis, which often spreads beyond treatment portals and may even be bilateral, have not been fully investigated. The purpose of this study was to identify important factors associated with severe radiation pneumonitis.Methods: 111 cases of primary lung cancer, treated with radiotherapy or chemoradiotherapy, were retrospectively analyzed.Results: Severe radiation pneumonitis occurred in 17 cases (15.3%). The ratio of interstitial change in lungs before radiotherapy and radiotherapy to the contralateral mediastinum with >40 Gy in the radiation pneumonitis group (RP group) was significantly higher than in patients without radiation pneumonitis (control group) (47.1% vs 5.3%; P< 0.001 and 58.8% vs 27.7%; P = 0.037, respectively). Using logistic regression analysis, interstitial changes before radiotherapy and radiotherapy to the contralateral mediastinum of >40 Gy were significant risk factors associated with severe radiation pneumonitis.Conclusions: These data suggest that pre-existing interstitial changes detected by chest radiography or computed tomography and radiotherapy to the contralateral mediastinum (>40 Gy) may predict the development of severe radiation pneumonitis.
Takeyuki Makimoto, Satoshi Tsuchiya, Kazushige Hayakawa, Ryusei Saitoh, Masatomo Mori
doi: 10.1093/jjco/29.4.192pmid: 10340042
Background: Risk factors for severe radiation pneumonitis, which often spreads beyond treatment portals and may even be bilateral, have not been fully investigated. The purpose of this study was to identify important factors associated with severe radiation pneumonitis. Methods: 111 cases of primary lung cancer, treated with radiotherapy or chemoradiotherapy, were retrospectively analyzed. Results: Severe radiation pneumonitis occurred in 17 cases (15.3%). The ratio of interstitial change in lungs before radiotherapy and radiotherapy to the contralateral mediastinum with >40 Gy in the radiation pneumonitis group (RP group) was significantly higher than in patients without radiation pneumonitis (control group) (47.1% vs 5.3%; P < 0.001 and 58.8% vs 27.7%; P = 0.037, respectively). Using logistic regression analysis, interstitial changes before radiotherapy and radiotherapy to the contralateral mediastinum of >40 Gy were significant risk factors associated with severe radiation pneumonitis. Conclusions: These data suggest that pre-existing interstitial changes detected by chest radiography or computed tomography and radiotherapy to the contralateral mediastinum (>40 Gy) may predict the development of severe radiation pneumonitis. Key words Key words radiation pneumonitis risk factors primary lung cancer interstitial change Abbreviations RP radiation pneumonitis CT computed tomography PS performance status ECOG Eastern Cooperative Oncology Group MV megavolt BI Brinkman Index PaO 2 oxygenation LDH lactate dehydrogenase CRP C reactive protein ips. med. ipsilateral mediastinum cont. med. contralateral mediastinum DLco/VA permeability coefficient ARDS adult respiratory distress syndrome Sq squamous cell carcinoma Ad adenocarcinoma La large cell carcinoma A-aDO 2 alveolar arterial difference Sup. seg. the superior segment of the lower lobe r right 1 left UL upper lobe LL lower lobe emp. emphysema interst interstiitial change prim primary focus P cisplatin E etoposide V vindesine CB carboplatin CAV/PE combination consisting of cyclophosphamide, doxorubicin and vincristine alternating with etoposide plus cisplatin CPT-11 irinotecan seq sequentially cone concurrently © 1999 Foundation for Promotion of Cancer Research « Previous | Next Article » Table of Contents This Article Jpn. J. Clin. Oncol. (1999) 29 (4): 192-197. doi: 10.1093/jjco/29.4.192 » Abstract Free Full Text (HTML) Free Full Text (PDF) Free Classifications Original Articles Services Article metrics Alert me when cited Alert me if corrected Find similar articles Similar articles in Web of Science Similar articles in PubMed Add to my archive Download citation Request Permissions Citing Articles Load citing article information Citing articles via CrossRef Citing articles via Scopus Citing articles via Web of Science Citing articles via Google Scholar Google Scholar Articles by Makimoto, T. Articles by Mori, M. Search for related content PubMed PubMed citation Articles by Makimoto, T. Articles by Tsuchiya, S. Articles by Hayakawa, K. Articles by Saitoh, R. Articles by Mori, M. Related Content Load related web page information Share Email this article CiteULike Delicious Facebook Google+ Mendeley Twitter What's this? Search this journal: Advanced » Current Issue November 2015 45 (11) Alert me to new issues The Journal About this journal JJCO Editorial Office Rights & Permissions Dispatch date of the next issue This journal is a member of the Committee on Publication Ethics (COPE) We are mobile – find out more Journals Career Network Impact factor: 2.016 5-Yr impact factor: 2.036 Editor-in-Chief Tadao Kakizoe View full editorial board View/Download Reviewer Board List Thank you: Reviewers of 2014 For Authors Instructions to authors Online submission Online submission instruction Open Access options for authors - visit Oxford Open This journal enables compliance with the NIH Public Access Policy Self-archiving policy Alerting Services Email table of contents Email Advance Access CiteTrack XML RSS feed Corporate Services Advertising sales Reprints Supplements
doi: 10.1093/jjco/29.4.198pmid: 10340043
Background: To establish the correlation between tumor appearance on CT and tumor histology in renal cell carcinomas. Methods: The density and attenuation patterns of 96 renal cell carcinomas, each ≤5 cm in greatest diameter, were studied by non-enhanced CT and early and late after bolus injection of contrast medium using dynamic CT The density and attenuation patterns and pathological maps of each tumor were individually correlated. Results: High attenuated areas were present in 72 of the 96 tumors on early enhanced dynamic CT scanning. All 72 high attenuated areas were of the clear cell renal cell carcinoma and had alveolar architecture. The remaining 24 tumors that did not demonstrate high attenuated foci on early enhanced scanning included three clear cell, nine granular cell, six papillary, five chromophobe and one collecting duct type. With respect to tumor architecture, all clear cell tumors of alveolar architecture demonstrated high attenuation on early enhanced scanning. Conclusion: Clear cell renal cell carcinomas of alveolar architecture show high attenuation on early enhanced dynamic CT scanning. A larger number of patients are indispensable to obtaining clear results. However, these findings seem to be an important clue to the diagnosis of renal cell carcinomas as having an alveolar structure. Key words Key words renal cell carcinoma computed tomography attenuation © 1999 Foundation for Promotion of Cancer Research « Previous | Next Article » Table of Contents This Article Jpn. J. Clin. Oncol. (1999) 29 (4): 198-203. doi: 10.1093/jjco/29.4.198 » Abstract Free Full Text (HTML) Free Full Text (PDF) Free Classifications Original Articles Services Article metrics Alert me when cited Alert me if corrected Find similar articles Similar articles in Web of Science Similar articles in PubMed Add to my archive Download citation Request Permissions Citing Articles Load citing article information Citing articles via CrossRef Citing articles via Scopus Citing articles via Web of Science Citing articles via Google Scholar Google Scholar Articles by Fujimoto, H. Articles by Kakizoe, T. Search for related content PubMed PubMed citation Articles by Fujimoto, H. Articles by Wakao, F. Articles by Moriyama, N. Articles by Tobisu, K. Articles by Sakamoto, M. Articles by Kakizoe, T. Related Content Load related web page information Share Email this article CiteULike Delicious Facebook Google+ Mendeley Twitter What's this? Search this journal: Advanced » Current Issue November 2015 45 (11) Alert me to new issues The Journal About this journal JJCO Editorial Office Rights & Permissions Dispatch date of the next issue This journal is a member of the Committee on Publication Ethics (COPE) We are mobile – find out more Journals Career Network Impact factor: 2.016 5-Yr impact factor: 2.036 Editor-in-Chief Tadao Kakizoe View full editorial board View/Download Reviewer Board List Thank you: Reviewers of 2014 For Authors Instructions to authors Online submission Online submission instruction Open Access options for authors - visit Oxford Open This journal enables compliance with the NIH Public Access Policy Self-archiving policy Alerting Services Email table of contents Email Advance Access CiteTrack XML RSS feed Corporate Services Advertising sales Reprints Supplements
Fujimoto, Hiroyuki; Wakao, Fumihiko; Moriyama, Noriyuki; Tobisu, Kenichi; Sakamoto, Michiie; Kakizoe, Tadao
doi: N/Apmid: N/A
Background: To establish the correlation between tumor appearance on CT and tumor histology in renal cell carcinomas.Methods: The density and attenuation patterns of 96 renal cell carcinomas, each ≤5 cm in greatest diameter, were studied by non-enhanced CT and early and late after bolus injection of contrast medium using dynamic CT The density and attenuation patterns and pathological maps of each tumor were individually correlated.Results: High attenuated areas were present in 72 of the 96 tumors on early enhanced dynamic CT scanning. All 72 high attenuated areas were of the clear cell renal cell carcinoma and had alveolar architecture. The remaining 24 tumors that did not demonstrate high attenuated foci on early enhanced scanning included three clear cell, nine granular cell, six papillary, five chromophobe and one collecting duct type. With respect to tumor architecture, all clear cell tumors of alveolar architecture demonstrated high attenuation on early enhanced scanning.Conclusion: Clear cell renal cell carcinomas of alveolar architecture show high attenuation on early enhanced dynamic CT scanning. A larger number of patients are indispensable to obtaining clear results. However, these findings seem to be an important clue to the diagnosis of renal cell carcinomas as having an alveolar structure.
Gohji, Kazuo; Ono, Yoshiharu; Takenaka, Atsushi; Nomi, Masashi; Okamoto, Masayuki; Yuen, Keiji; Fujii, Akio
doi: N/Apmid: N/A
Background: To determine the long-term effects and toxicity of multidrug chemotherapy for advanced urothelial cancer.Methods: Forty patients with metastatic urothelial cancer were treated with a new combination chemotherapy, MVP-CAB (methotrexate, doxorubicin, vincristine, cyclophosphamide, bleomycin and cisplatin every 28 days). Of the 40 patients, 26 had not undergone prior chemotherapy or radiotherapy; the remaining 14 patients had undergone prior cisplatin-based chemotherapy.Results: The clinical response rate to MVP-CAB therapy for all 40 patients was 63% [complete response (CR), six patients; partial response (PR), 19 patients]. The median duration of the effects was 22 and 13 months in the patients with CR and PR, respectively. The clinical response rate for the 26 patients without prior chemotherapy was 77% (CR, four patients; PR, 16 patients). The rate for the 14 patients with prior chemotherapy was 36% (CR, two patients; PR, three patients). The response rate according to metastatic site was highest for the liver (80%), followed by the lymph nodes (74%) and lungs (67%). The effect on bone metastasis was poor (22%). There was good compliance with the MVP-CAB chemotherapy regimen and toxicity was tolerable. The 1-, 3- and 5-year overall survival rates were 42.5, 10 and 5%, respectively.Conclusions: MVP-CAB combination chemotherapy was found to be effective for the treatment of advanced urothelial cancer, especially for liver metastasis.
Kazuo Gohji, Yoshiharu Ono, Atsushi Takenaka, Masashi Nomi, Masayuki Okamoto, Keiji Yuen, Akio Fujii
doi: 10.1093/jjco/29.4.204pmid: 10340044
Background: To determine the long-term effects and toxicity of multidrug chemotherapy for advanced urothelial cancer. Methods: Forty patients with metastatic urothelial cancer were treated with a new combination chemotherapy, MVP-CAB (methotrexate, doxorubicin, vincristine, cyclophosphamide, bleomycin and cisplatin every 28 days). Of the 40 patients, 26 had not undergone prior chemotherapy or radiotherapy; the remaining 14 patients had undergone prior cisplatin-based chemotherapy. Results: The clinical response rate to MVP-CAB therapy for all 40 patients was 63% (complete response (CR), six patients; partial response (PR), 19 patients). The median duration of the effects was 22 and 13 months in the patients with CR and PR, respectively. The clinical response rate for the 26 patients without prior chemotherapy was 77% (CR, four patients; PR, 16 patients). The rate for the 14 patients with prior chemotherapy was 36% (CR, two patients; PR, three patients). The response rate according to metastatic site was highest for the liver (80%), followed by the lymph nodes (74%) and lungs (67%). The effect on bone metastasis was poor (22%). There was good compliance with the MVP-CAB chemotherapy regimen and toxicity was tolerable. The 1-, 3- and 5-year overall survival rates were 42.5, 10 and 5%, respectively. Conclusions: MVP-CAB combination chemotherapy was found to be effective for the treatment of advanced urothelial cancer, especially for liver metastasis. Keywords Key words urothelial cancer metastasis chemotherapy Abbreviations CR complete response PR partia! response PD progressive disease MTX methotrexate VBL vinblastine ADM doxorubicin CDDP cisplatin CPM cyclophosphamide BLM bleomycin VCR vincristine © 1999 Foundation for Promotion of Cancer Research « Previous | Next Article » Table of Contents This Article Jpn. J. Clin. Oncol. (1999) 29 (4): 204-208. doi: 10.1093/jjco/29.4.204 » Abstract Free Full Text (HTML) Free Full Text (PDF) Free Classifications Original Articles Services Article metrics Alert me when cited Alert me if corrected Find similar articles Similar articles in Web of Science Similar articles in PubMed Add to my archive Download citation Request Permissions Citing Articles Load citing article information Citing articles via CrossRef Citing articles via Scopus Citing articles via Web of Science Citing articles via Google Scholar Google Scholar Articles by Gohji, K. Articles by Fujii, A. Search for related content PubMed PubMed citation Articles by Gohji, K. Articles by Ono, Y. Articles by Takenaka, A. Articles by Nomi, M. Articles by Okamoto, M. Articles by Yuen, K. Articles by Fujii, A. Related Content Load related web page information Share Email this article CiteULike Delicious Facebook Google+ Mendeley Twitter What's this? Search this journal: Advanced » Current Issue November 2015 45 (11) Alert me to new issues The Journal About this journal JJCO Editorial Office Rights & Permissions Dispatch date of the next issue This journal is a member of the Committee on Publication Ethics (COPE) We are mobile – find out more Journals Career Network Impact factor: 2.016 5-Yr impact factor: 2.036 Editor-in-Chief Tadao Kakizoe View full editorial board View/Download Reviewer Board List Thank you: Reviewers of 2014 For Authors Instructions to authors Online submission Online submission instruction Open Access options for authors - visit Oxford Open This journal enables compliance with the NIH Public Access Policy Self-archiving policy Alerting Services Email table of contents Email Advance Access CiteTrack XML RSS feed Corporate Services Advertising sales Reprints Supplements
Showing 1 to 10 of 28 Articles